Tesla
TSLA
NVIDIA
NVDA
Palantir
PLTR
4
Strategy
MSTR
5
SoundHound AI
SOUN
US Stock MarketDetailed Quotes
CTOR Citius Oncology
- 1.190
- 0.0000.00%
Close Feb 28 16:00 ET
- 1.190
- 0.0000.00%
Post 20:01 ET
85.15MMarket Cap-3.68P/E (TTM)
1.200High1.110Low12.64KVolume1.150Open1.190Pre Close14.59KTurnover0.23%Turnover RatioLossP/E (Static)71.55MShares49.00052wk High2.06P/B6.55MFloat Cap0.85052wk Low--Dividend TTM5.50MShs Float49.000Historical High--Div YieldTTM7.56%Amplitude0.850Historical Low1.154Avg Price1Lot Size
About Citius Oncology Company
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
Company Profile
SymbolCTOR
Company NameCitius Oncology
Listing DateDec 8, 2022
Founded2021
CEOMr. Leonard L. Mazur
MarketNASDAQ
Fiscal Year Ends09-30
Address11 Commerce Drive,1st floor
CityCranford
ProvinceNew Jersey
CountryUnited States of America
Zip Code07016
Websitehttps://www.citiusonc.com
Company Executives
- Name
- Position
- Salary
- Leonard L. Mazur
- Chairman of the Board and Chief Executive Officer
- --
- Jaime Bartushak
- Chief Financial Officer, Principal Accounting Officer and Treasurer
- --
- Dr. Myron Czuczman, M.D.
- Chief Medical Officer and President
- --
- Myron Z. Holubiak
- Director and Secretary
- --
- Robert J. Smith
- Independent Director
- --
- Joel D. Mayersohn
- Independent Director
- --
- Dennis M. McGrath, C.P.A.
- Independent Director
- --
- Suren G. Dutia
- Independent Director
- --
- Dr. Eugene Holuka
- Independent Director
- --
- Carol Webb
- Independent Director
- --